Form 4: Arcutis EVP Sells Shares for Tax, 10b5-1 Plan

Arcutis Biotherapeutics' EVP and Chief Medical Officer, Patrick Burnett, sold shares of common stock in early February 2026, primarily to cover tax obligations related to RSU vesting and under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported two sales of common stock.
• On February 2, 2026, 3,675 shares were sold at a weighted average price of $25.4984 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The RSUs were granted on January 12, 2024, with 25% vesting annually on February 1st of each year, beginning February 1, 2025, subject to continued service.
• On February 4, 2026, an additional 9,794 shares were sold at a weighted average price of $25.8064 per share.
• This second transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, which has a plan end date of February 27, 2026.
• Following these transactions, Patrick Burnett beneficially owns 80,651 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales are routine for tax purposes and pre-scheduled under a 10b5-1 plan, which typically do not signal a change in fundamental company outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are common and generally not indicative of a change in management's outlook on the company. Similarly, sales executed under a pre-arranged 10b5-1 trading plan are typically scheduled in advance to allow insiders to sell shares without being accused of trading on material non-public information, and often reflect personal financial planning rather than a negative view of the company's prospects.

Key Dates

Recommendation

The reported insider sales are routine and pre-planned, primarily for tax obligations and personal financial management. They do not provide new fundamental information about Arcutis Biotherapeutics' operational performance or future prospects that would warrant a change in investment thesis. Investors should continue to hold based on the company's underlying business fundamentals.

Keywords

Arcutis Biotherapeutics, ARQT, Patrick Burnett, Insider Trading, Form 4, Stock Sale, RSU, 10b5-1 Plan